162 related articles for article (PubMed ID: 16052214)
1. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato AG; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Br J Cancer; 2005 Aug; 93(4):406-11. PubMed ID: 16052214
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
[TBL] [Abstract][Full Text] [Related]
3. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
Cappuzzo F; Mazzoni F; Gennari A; Donati S; Salvadori B; Orlandini C; Cetto GL; Molino A; Galligioni E; Mansutti M; Tumolo S; Lucentini A; Valduga F; Bartolini S; Crinò L; Conte PF
Br J Cancer; 2004 Jan; 90(1):31-5. PubMed ID: 14710202
[TBL] [Abstract][Full Text] [Related]
4. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Earl HM; Vallier AL; Hiller L; Fenwick N; Young J; Iddawela M; Abraham J; Hughes-Davies L; Gounaris I; McAdam K; Houston S; Hickish T; Skene A; Chan S; Dean S; Ritchie D; Laing R; Harries M; Gallagher C; Wishart G; Dunn J; Provenzano E; Caldas C;
Lancet Oncol; 2014 Feb; 15(2):201-12. PubMed ID: 24360787
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Schneeweiss A; Schuetz F; Rudlowski C; Hahn M; Lauschner I; Sinn HP; von Fournier D; Sohn C
Anticancer Drugs; 2005 Oct; 16(9):1023-8. PubMed ID: 16162980
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Conte PF; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
Breast Cancer Res Treat; 2001 Jul; 68(2):171-9. PubMed ID: 11688520
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Schneeweiss A; Huober J; Sinn HP; von Fournier D; Rudlowski C; Beldermann F; Krauss K; Solomayer E; Hamerla R; Wallwiener D; Bastert G
Eur J Cancer; 2004 Nov; 40(16):2432-8. PubMed ID: 15519516
[TBL] [Abstract][Full Text] [Related]
10. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Hamm JT; Wilson JW; Rastogi P; Lembersky BC; Tseng GC; Song YK; Kim W; Robidoux A; Raymond JM; Kardinal CG; Shalaby IA; Ansari R; Paik S; Geyer CE; Wolmark N;
Clin Breast Cancer; 2008 Jun; 8(3):257-63. PubMed ID: 18650156
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
13. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
15. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
17. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
18. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
[TBL] [Abstract][Full Text] [Related]
19. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
20. Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer.
Frutuoso C; Henriques I; Pazos I; Abraul E; Pego A; Belo J; Campos O; Gervásio H; de Oliveira C
Eur J Gynaecol Oncol; 2007; 28(6):447-50. PubMed ID: 18179134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
